Alaunos Therapeutics

Alaunos Therapeutics, formerly known atas NetEscapes, EasyWeb, and Ziopharm, is a Texas-based company specializing in developing solutions for the treatment of solid tumors through adoptive T cell receptor engineering (TCR-T) cell therapy.Thetherapy. The company was originally founded in 1998 and initially offered services related to Internet solutions. It is located in Houston, Texas and has partnerships with other healthcare-related organizations, such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute, to work on projects developing biotechnology platforms.

The company has developed solutions that engineer cell therapies to target Neoantigens (neoAg) arising from genomic mutations. Its solutions are designed to deliver tumor-specific killer T cells to large cancer patient populations that do not have many options for their treatments and therapies.

Alaunos Therapeutics has developed two platforms: Sleeping Beauty and hunTR. Sleeping Beauty is a non-viral, transposon/transposase system is used to introduce the TCR gene into autologous T cells from the patient. The hunTR platform stands for human neoantigen T-cell Receptor and it utilizes the company's TCR discovery process with a high-throughput TCR functional validation to streamline the addition of high-quality TCRs to the company's existing TCR-T cell therapy infrastructure.

Alaunos Therapeutics has developed two platforms: Sleeping Beauty and hunTR. Sleeping Beauty is a non-viral, transposon/transposase system used to introduce the TCR gene into autologous T cells from the patient. The hunTR platform stands for human neoantigen T-cell receptor, and it utilizes the company's TCR discovery process with a high-throughput TCR functional validation to streamline the addition of high-quality TCRs to the company's existing TCR-T cell therapy infrastructure.

Alaunos Therapeutics, formerly known at NetEscapes, EasyWeb, and Ziopharm, is a Texas-based specializing in developing solutions for the treatment of solid tumors through adoptive T cell receptor engineering (TCR-T) cell therapy.The company was originally founded in 1998 and initially offered services related to Internet solutions. It is located in Houston, Texas and has partnerships with other healthcare-related organizations, such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute, to work on projects developing biotechnology platforms.

The company has developed solutions that engineer cell therapies to target Neoantigens (neoAg) arising from genomic mutations. Its solutions are designed to deliver tumor-specific killer T cells to large cancer patient populations that do not have many options for their treatments and therapies.

Alaunos Therapeutics has developed two platforms: Sleeping Beauty and hunTR. Sleeping Beauty is a non-viral, transposon/transposase system is used to introduce the TCR gene into autologous T cells from the patient. The hunTR platform stands for human neoantigen T-cell Receptor and it utilizes the company's TCR discovery process with a high-throughput TCR functional validation to streamline the addition of high-quality TCRs to the company's existing TCR-T cell therapy infrastructure.

How the hunTR platform works